CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 3.95: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.30BCNY641.54M · vs all stocks (USD)
Revenue (TTM)
476.33MCNY71.08M · vs all stocks (USD)
Profit Margin
-19.03%vs Medical Devices peers
Beta
0.1240xvs all stocks
52-Week Change
-34.69%vs all stocks
Market Capitalization
4.30BCNY641.54M · vs all stocks (USD)
Enterprise Value
3.26BCNY487.03M · vs all stocks (USD)
Price to Sales (TTM)
9.03xvs Medical Devices peers
Price to Book (MRQ)
2.56xvs Medical Devices peers
Enterprise to Revenue
6.85xvs Medical Devices peers
Enterprise to EBITDA
-48.19xvs Medical Devices peers
Gross Margin
45.78%vs Medical Devices peers
Profit Margin
-19.03%vs Medical Devices peers
Operating Margin
-28.70%vs Medical Devices peers
Return on Assets (TTM)
-2.17%vs Medical Devices peers
Return on Equity (TTM)
-5.24%vs Medical Devices peers
Revenue (TTM)
476.33MCNY71.08M · vs all stocks (USD)
Revenue per Share (TTM)
1.19CNYUpdated Sep 21, 2026Quarterly Revenue Growth
18.80%vs Medical Devices peers
Gross Profit (TTM)
155.96MCNY23.27M · vs all stocks (USD)
EBITDA (TTM)
63.09MCNY9.41M · vs all stocks (USD)
Net Income (TTM)
-90.63MCNY-13.52M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
12.30%vs Medical Devices peers
Operating Cash Flow (TTM)
29.83MCNY4.45M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-30.94MCNY-4.62M · vs all stocks (USD)
5-Year Average Dividend Yield
1.31%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
468.00MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
243.14MCNYFY2025 · Dec 31, 2025Gross Profit
224.86MCNYFY2025 · Dec 31, 2025Operating Income
-13.98MCNY-2.09M · vs all stocks (USD)
Pre-tax Income
-26.89MCNYFY2025 · Dec 31, 2025Income Tax Expense
-2.46MCNYFY2025 · Dec 31, 2025Net Income
-24.42MCNYFY2025 · Dec 31, 2025EBIT
10.54MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
63.09MCNYFY2025 · Dec 31, 2025Research & Development
91.66MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
101.13MCNYFY2025 · Dec 31, 2025Other Operating Expenses
8.75MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
49.80MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
37.43MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
407.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
407.06MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-24.42MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-4.21MCNYFY2025 · Dec 31, 2025Free Cash Flow
-53.54MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
982.72MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-24.42MCNYFY2025 · Dec 31, 2025Other Non-cash Items
19.53MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.46MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
11.14MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.33MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.80BCNYFY2025 · Dec 31, 2025Sale of Investments
4.08BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
227.79MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
275.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-120.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-112.11MCNYFY2025 · Dec 31, 2025Other Financing Charges
20.63MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
63.52MCNYFY2025 · Dec 31, 2025Shares Outstanding
401.80MSharesUpdated Sep 21, 2026Float Shares
198.16MSharesUpdated Sep 21, 2026% Held by Insiders
52.15%vs all stocks
% Held by Institutions
1.65%vs all stocks
Total Cash (MRQ)
1.90BCNY283.47M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.73CNYUpdated Sep 21, 2026Total Debt (MRQ)
864.19MCNY128.95M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5137xvs Medical Devices peers
Current Ratio (MRQ)
12.21xvs Medical Devices peers
Book Value per Share (MRQ)
4.19CNYUpdated Sep 21, 2026Total Assets
2.77BCNY413.52M · vs all stocks (USD)
Total Current Assets
2.34BCNYFY2025 · Dec 31, 2025Total Liabilities
1.04BCNYFY2025 · Dec 31, 2025Total Non-current Assets
427.44MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
758.55MCNYFY2025 · Dec 31, 2025Total Current Liabilities
279.50MCNYFY2025 · Dec 31, 2025Cash
982.62MCNYFY2025 · Dec 31, 2025Cash Equivalents
104.87KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
982.72MCNYFY2025 · Dec 31, 2025Other Short-term Investments
631.77MCNYFY2025 · Dec 31, 2025Accounts Receivable
50.05MCNYFY2025 · Dec 31, 2025Inventory
229.58MCNYFY2025 · Dec 31, 2025Accounts Payable
11.47MCNYFY2025 · Dec 31, 2025Short-term Debt
216.08MCNYFY2025 · Dec 31, 2025Long-term Debt
751.40MCNYFY2025 · Dec 31, 2025Common Stock (Book)
401.80MCNYFY2025 · Dec 31, 2025Retained Earnings
767.53MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.73BCNY258.62M · vs all stocks (USD)
52-Week Low
9.98CNYUpdated Sep 21, 202652-Week High
18.10CNYUpdated Sep 21, 202652-Week Change
-34.69%vs all stocks
Beta
0.1240xvs all stocks
50-Day MA
11.10CNYUpdated Sep 21, 2026200-Day MA
13.00CNYUpdated Sep 21, 2026Avg 10-Day Volume
2.26MSharesUpdated Sep 21, 2026Avg 30-Day Volume
3.36MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.2200CNYUpdated Sep 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Long-Term Debt A High Share Of Total Liabilities, Short-Term Debt A High Share Of Current Liabilities
Borrowing makes up most of what it owes, both the long-dated part and the part due soon.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.46Profit Margin: -0.19
Financial Health
Altman Z-Score 3.95: safe zoneNotable
Altman Z-Score: 3.95
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Lionco Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hvsen Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ProKidney Corp
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sailun Biotech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Bitfarms Ltd.
2 interpretationsLong-Term Debt A High Share Of Total Liabilities, Short-Term Debt A High Share Of Current LiabilitiesCash Elevated Relative to Current Liabilities and Total Assets
Opendoor Technologies Inc.
2 interpretationsLong-Term Debt A High Share Of Total Liabilities, Short-Term Debt A High Share Of Current LiabilitiesCash Elevated Relative to Current Liabilities and Total Assets
Anbio Biotechnology Limited
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets